None listed
Conditions
Brief summary
This project aims to investigate the effectiveness of daily supplementation with Glycomax 'trademark' Lactoferrin and bovine whey-derived Ig-rich fraction on symptoms of atopic dermatitis. The study is a double-blind placebo-controlled parallel trial and consists of two phases, a 56 day supplement period followed by a four week post supplement follow up. The study group will consist of both male and females adults (n=45). Participants will range in age from 18-60 years with a confirmed diagnosis of atopic dermatitis made by a dermatologist.
Interventions
Daily oral supplementation for 56 days with a combined 250mg each of bovine whey derived Glycomax 'trademark' lactoferrin and bovine whey-Ig rich fraction or a Placebo, both in tablet form.
Each participant will also be provided with a hypoallergenic sorbolene cream (Dermeze Sensitive Cream) for the relief of dryness as required at their discretion.
Supplements and the Dermeze cream will be collected at the end of the study for assessing adherence.
Sponsors
Griffith University
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
Presence of atopic dermatitis according to physician diagnosis using SCORAD
Exclusion criteria
1 is lactose intolerant 2 consumes fish oil, probiotics, prebiotics, whey protein supplements during the trial period 3 requires insulin use (for treatment of diabetes) 4 has history of liver, kidney or thyroid disease 5 uses anti-inflammatory or immune-modulating medications 6 has heavy alcohol consumption 7 is pregnant or intends to become pregnant
Outcome results
None listed